Business Description
Tempest Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US87978U2078
Total Employee Number:
4Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.08 | |||||
Debt-to-Equity | 9.56 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 45.2 | |||||
3-Year EPS without NRI Growth Rate | 46 | |||||
3-Year FCF Growth Rate | 43.4 | |||||
3-Year Book Growth Rate | -60.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 45.05 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.14 | |||||
9-Day RSI | 28.13 | |||||
14-Day RSI | 29.55 | |||||
3-1 Month Momentum % | -6.71 | |||||
6-1 Month Momentum % | -46.69 | |||||
12-1 Month Momentum % | -77.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.74 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -82.6 | |||||
Shareholder Yield % | 4.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -620.08 | |||||
ROA % | -212.4 | |||||
ROIC % | -384.2 | |||||
3-Year ROIIC % | -139.08 | |||||
ROC (Joel Greenblatt) % | -506.63 | |||||
ROCE % | -303.23 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 18.5 | |||||
Price-to-Tangible-Book | 18.5 | |||||
EV-to-EBIT | -0.55 | |||||
EV-to-Forward-EBIT | -1.16 | |||||
EV-to-EBITDA | -0.56 | |||||
EV-to-Forward-EBITDA | -1.16 | |||||
EV-to-FCF | -0.9 | |||||
Earnings Yield (Greenblatt) % | -181.82 | |||||
FCF Yield % | -148.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TPST
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tempest Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.01 | ||
| Beta | -7.4663 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 3.79 | ||
| Volatility % | 93.61 | ||
| 14-Day RSI | 29.55 | ||
| 14-Day ATR ($) | 0.088752 | ||
| 20-Day SMA ($) | 1.22275 | ||
| 12-1 Month Momentum % | -77.5 | ||
| 52-Week Range ($) | 1.02 - 12.23 | ||
| Shares Outstanding (Mil) | 15.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tempest Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tempest Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-31 13:00 | In 184 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 41 days | ||
| First quarter earnings results for 2026 | 2026-05-20 | 1.78 (-2.20%) | ||
| Annual report for 2025 | 2026-03-30 | 1.73 (+8.12%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 1.73 (+8.12%) | ||
| General meeting for 2025 | 2025-12-31 13:00 | 2.84 (-2.41%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 9.12 (-7.51%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 7.36 (+5.75%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 6.87 (+4.09%) |
Show
Entries
Tempest Therapeutics Inc Frequently Asked Questions
What is Tempest Therapeutics Inc(TPST)'s stock price today?
The current price of TPST is $1.11. The 52 week high of TPST is $12.23 and 52 week low is $1.02.
When is next earnings date of Tempest Therapeutics Inc(TPST)?
The next earnings date of Tempest Therapeutics Inc(TPST) is 2026-08-11 Est..
Does Tempest Therapeutics Inc(TPST) pay dividends? If so, how much?
Tempest Therapeutics Inc(TPST) does not pay dividend.
Guru Commentaries on NAS:TPST
No articles.
Press Release
Articles on Tempest Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers